{
  "pmcid": "11071679",
  "sha256": "16b6b80ad8189e6d9d3abcb7a343314d49b6e635563ce22799156063aa65a7f7",
  "timestamp_utc": "2025-11-09T23:12:13.420412+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.517304391721357,
    "reading_ease": 7.813910482921102,
    "word_count": 283
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Cardioprotective Strategies in Cardioplegic Solutions"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "randomised controlled trial included adult patients undergoing cardiac surgery with cardioplegia"
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at a cardiovascular surgery center... Eligibility criteria encompassed individuals with cardiovascular pathologies"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised into two groups: intervention (cardioplegic solution with adjuvants) and control (standard cardioplegic solution)"
      },
      "Objective": {
        "score": 1,
        "evidence": "To evaluate the impact of adjuvant-enhanced cardioplegic solutions on myocardial protection"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the extent of myocardial damage, assessed by cardiac biomarkers, over a 48-hour postoperative period"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised, 100 to each group, between January 2020 and June 2021"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 in the intervention group and 97 in the control group, using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group demonstrated a significant reduction in myocardial damage (mean difference = 5.2, 95% CI 3.1 to 7.3; p = 0.01)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the intervention group and 1% in the control group experiencing side effects"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institute of Health"
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}